Trial Profile
"Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a treatment that evaluates the effectiveness and the safety of oral BIBF 1120 in combination with standard docetaxel therapy, which can be administered (at the discretion of the referring physician) with tri-weekly or weekly schedule
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2020
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SENECA
- 10 Sep 2019 Status changed to active, no longer recruiting as per results presented at the 20th World Conference on Lung Cancer
- 10 Sep 2019 Results evaluating 16 patients previously treated with immunotherapy and comparing them to the rest of patient population presented at the 20th World Conference on Lung Cancer
- 26 Sep 2018 Results (From January 2016 to data cut-off, on 30th March 2018, n= 197) presented at the 19th World Conference on Lung Cancer